Bulk Pharmaceutical API Sources for LYOPHILIZED CYTOXAN

Bulk Pharmaceutical API Sources for LYOPHILIZED CYTOXAN

Vendor	Vendor Homepage	Vendor Sku	API Url
Vitas-M Laboratory		STK177249
Molport		MolPort-001-783-420
TCI (Tokyo Chemical Industry)		C2236

Bulk Active Pharmaceutical Ingredient Sources for Lyophilized Cytoxan (Cyclophosphamide)

Last updated: February 19, 2026

What are the primary sources for bulk cyclophosphamide—specifically, the active pharmaceutical ingredient (API)—used in lyophilized Cytoxan?

Major suppliers of cyclophosphamide API operate globally, mainly in India, China, and Europe, with varying quality standards and regulatory compliance. These sources support pharmaceutical manufacturers primarily for oncology, autoimmune, and transplant indications.

Who are the leading API manufacturers for cyclophosphamide?

Manufacturer	Country	GMP Certification	Production Capacity	Notes
Dr. Reddy’s Laboratories	India	Yes	~1,000 kg/month	Approved by major regulators, including the US FDA and EMA
CIPLA	India	Yes	800–1,200 kg/month	Global supplier, follows strict quality protocols
Hanlim Pharmaceutical	South Korea	Yes	Not publicly disclosed	Focuses on oncology APIs with high purity standards
Shandong Yuhuang Pharmaceutical	China	Yes	Estimated 1,000–2,000 kg/month	Supplies primarily for domestic markets and exports
Fudan Zhongke Pharmaceutical	China	Yes	High-volume production	Meets international GMP standards

What are the quality and regulatory considerations?

• US FDA and EMA approve certain API suppliers based on GMP adherence.
• Suppliers often provide Certificates of Analysis (CoA), demonstrating compliance with pharmacopeial standards.
• Suppliers certified under ISO 9001 or similar standards ensure quality controls.
• Variability exists in the active ingredient's purity (typically >99%), which impacts drug safety and efficacy.

How do distinctions in manufacturing impact sourcing decisions?

• US/EU suppliers typically undergo more rigorous audits, easing regulatory approval in Western markets.
• Indian and Chinese sources exhibit higher capacity and cost advantages but may require additional quality verification.
• Batch consistency is critical; suppliers with validated process controls are preferred for consistent delivery.
• Supply chain risks include geopolitical factors and export restrictions occasionally limiting access.

How does pricing vary among bulk API sources?

Supplier Region	Price Range per kg (USD)	Key Influences
India	$3,500–$5,000	Cost efficiencies, scale
China	$2,800–$4,500	Competitive pricing, capacity
South Korea	$4,500–$6,000	Higher quality standards, smaller scale
European Union	Often custom-priced	Strict GMP, regulatory compliance

What are the supply chain forecasts?

• API supply volume for cyclophosphamide is expected to grow at 4–6% CAGR through 2025.
• Anticipated capacity expansion in India and China aims to address rising demand.
• Weaker supply chain resilience can lead to shortages, especially amid geopolitical or pandemic-related disruptions.

Key Takeaways

• Multiple global suppliers produce high-quality cyclophosphamide API for lyophilized Cytoxan.
• Indian and Chinese manufacturers dominate on capacity and cost, with varying regulatory compliance.
• US and European supply chains favor suppliers with stringent GMP standards, but often at higher prices.
• Sourcing decisions hinge on assessing quality, regulatory approval, supply stability, and cost.
• Capacity expansion is expected, but supply chain vulnerabilities persist.

FAQs

1. Which countries are the primary sources of cyclophosphamide API?
India, China, and South Korea are the main manufacturers, with India and China leading in volume and cost.

2. How does API quality influence the final lyophilized Cytoxan product?
High API purity (>99%) and compliance with pharmacopeial standards ensure safety, efficacy, and regulatory approval.

3. Are there regulatory barriers to sourcing from Chinese API manufacturers?
Regulatory agencies may require additional validation and evidence of GMP compliance; approvals depend on the exporting country’s audit and certification.

4. What is the typical lead time for API procurement?
Lead times range from 4 to 12 weeks, depending on supplier location, certification, and order volume.

5. Is there a risk of API shortages from these sources?
Yes. Disruptions due to geopolitical issues, regulatory changes, or pandemic-related supply chain constraints can lead to shortages.

---

References

1. U.S. FDA. (2022). Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
2. European Medicines Agency. (2022). European pharmacopoeia standards for active pharmaceutical ingredients.
3. GlobalData. (2023). API manufacturing market analysis.
4. Indian Pharma. (2022). Indian API industry overview.
5. China Pharmaceutical Industry Association. (2022). API production capacity report.